Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice

Neuroscience Letters

Volumn 507, Issue 2, 2012, Pages 137-142

  Emmer, Kristel L ^a   Covy, Jason P ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Synuclein; Aggregation; Amyloid; Parkinson disease; Pathology; Transgenic

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; PRESENILIN 1;

ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; HUMAN; HUMAN CELL; MOUSE; MUTATION; NEURITE; NONHUMAN; PARKINSON DISEASE; PRION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; BRAIN; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCK-IN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84855320770     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.12.005     Document Type: Article

References (55)

1. Atwood C.S., Obrenovich M.E., Liu T., Chan H., Perry G., Smith M.A., Martins R.N. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res. Brain Res. Rev. 2003, 43:1-16.
2. Braak H., Bohl J.R., Muller C.M., Rub U., de Vos R.A., Del T.K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 2006, 21:2042-2051.
3. Canevari L., Abramov A.Y., Duchen M.R. Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem. Res. 2004, 29:637-650.
4. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
5. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
6. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 2005, 74:29-52.
7. Cronford M.E., Chang L., Miller B.L. The neuropathology of Parkinsonism: an overview. Brain Cogn. 1995, 28:321-341.
8. Dawson T.M., Ko H.S., Dawson V.L. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
9. Duda J.E., Giasson B.I., Gur T.L., Montine T.J., Robertson D., Biaggioni I., Hurtig H.I., Stern M.B., Gollomp S.M., Grossman M., Lee V.M.Y., Trojanowski J.Q. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J. Neuropathol. Exp. Neurol. 2000, 59:830-841.
10. Flood D.G., Reaume A.G., Dorfman K.S., Lin Y.G., Lang D.M., Trusko S.P., Savage M.J., Annaert W.G., De Strooper B., Siman R., Scott R.W. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol. Aging 2002, 23:335-348.
11. Forman M.S., Lee V.M., Trojanowski J.Q. Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron 2005, 47:479-482.
12. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
13. Fraser P.E., Yang D.S., Yu G., Levesque L., Nishimura M., Arawaka S., Serpell L.C., Rogaeva E., George-Hyslop P. Presenilin structure, function and role in Alzheimer disease. Biochim. Biophys. Acta 2000, 1502:1-15.
14. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
15. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 1999, 56:33-39.
16. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanoswki J.Q., Lee V.M.Y., Neuronal α-Synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002, 34:521-533.
17. Giasson B.I., Jakes R., Goedert M., Duda J.E., Leight S., Trojanowski J.Q., Lee V.M.Y. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 2000, 59:528-533.
18. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M.Y. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 1999, 274:7619-7622.
19. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
20. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
21. Goedert M., Clavaguera F., Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010, 33:317-325.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
23. Ishikawa A., Piao Y.S., Miyashita A., Kuwano R., Onodera O., Ohtake H., Suzuki M., Nishizawa M., Takahashi H. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann. Neurol. 2005, 57:429-434.
24. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
25. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
26. Jensen P.H., Hojrup P., Hager H., Nielsen M.S., Jacobsen L., Olesen O.F., Gliemann J., Jakes R. Binding of Aβ to α- and β-synucleins: identification of segments in α-synuclein/NAC precursor that binds Aβ and NAC. Biochem. J. 1997, 323(Pt 2):539-546.
27. Jimenez-Escrig A., Rabano A., Guerrero C., Simon J., Barquero M.S., Guell I., Ginestal R.C., Montero T., Orensanz L. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur. J. Neurol. 2004, 11:663-669.
28. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
29. Kimberly W.T., Wolfe M.S. Identity and function of gamma-secretase. J. Neurosci. Res. 2003, 74:353-360.
30. Koo E.H., Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med. 2004, 10(Suppl.):S26-S33.
31. Kurata T., Kawarabayashi T., Murakami T., Miyazaki K., Morimoto N., Ohta Y., Takehisa Y., Nagai M., Ikeda M., Matsubara E., Westaway D., Hyslop P.S., Harigaya Y., Kamiya T., Shoji M., Abe K. Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. J. Neurosci. Res. 2007, 85:2246-2252.
32. Lee E.B., Skovronsky D.M., Abtahian F., Doms R.W., Lee V.M. Secretion and intracellular generation of truncated abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J. Biol. Chem. 2003, 278:4458-4466.
33. Lee S.J., Desplats P., Sigurdson C., Tsigelny I., Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat. Rev. Neurol. 2010, 6:702-706.
34. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 2009, 18:R48-R59.
35. Lippa C.F., Fujiwara H., Mann D.M., Giasson B., Baba M., Schmidt M.L., Nee L.E., O'Connell B., Pollen D.A., George-Hyslop P., Ghetti B., Nochlin D., Bird T.D., Cairns N.J., Lee V.M.Y., Iwatsubo T., Trojanowski J.Q. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 1998, 153:1365-1370.
36. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., Mucke L. beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12245-12250.
37. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
38. Norris E.H., Giasson B.I., Lee V.M. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 2004, 60:17-54.
39. Periz G., Fortini M.E. Functional reconstitution of gamma-secretase through coordinated expression of presenilin, nicastrin, Aph-1, and Pen-2. J. Neurosci. Res. 2004, 77:309-322.
40. Poewe W. Non-motor symptoms in Parkinson's disease. Eur. J. Neurol. 2008, 15(Suppl. 1):14-20.
41. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
42. Selkoe D.J. The origins of Alzheimer's disease. JAMA 2000, 283:1615-1617.
43. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
44. Siman R., Reaume A.G., Savage M.J., Trusko S., Lin Y.G., Scott R.W., Flood D.G. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J. Neurosci. 2000, 20:8717-8726.
45. Simuni T., Hurtig H.I. Parkinson's disease: the clinical picture. Neurodegenerative Dementias 2000, 193-203. McGraw-Hill, New York. C.M. Clark, J.Q. Trojanoswki (Eds.).
46. Snider B.J., Norton J., Coats M.A., Chakraverty S., Hou C.E., Jervis R., Lendon C.L., Goate A.M., McKeel D.W., Morris J.C. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch. Neurol. 2005, 62:1821-1830.
47. Spillantini M.G., Schmidt M.L., Lee V.M.Y., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
48. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
49. Terai K., Iwai A., Kawabata S., Tasaki Y., Watanabe T., Miyata K., Yamaguchi T. Beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 2001, 104:299-310.
50. Waxman E.A., Duda J.E., Giasson B.I. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 2008, 116:37-46.
51. Waxman E.A., Giasson B.I. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim. Biophys. Acta 2008, 1792:616-624.
52. Waxman E.A., Giasson B.I. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 2008, 67:402-416.
53. Wilson C.A., Doms R.W., Lee V.M.Y Intracellular APP processing and Aβ produciton in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1999, 58:787-794.
54. Yang F., Ueda K., Chen P., Ashe K.H., Cole G.M. Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res. 2000, 853:381-383.
55. Yokota O., Terada S., Ishizu H., Ujike H., Ishihara T., Nakashima H., Yasuda M., Kitamura Y., Ueda K., Checler F., Kuroda S. NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases. Acta Neuropathol. 2002, 104:637-648.